Richard M. Bergenstal
Expertise in
6
conditions

Dr. Richard M. Bergenstal

Endocrinology
3800 Park, 
Nicollet, MN 
Referral required
Expertise in
6
conditions
3800 Park, 
Nicollet, MN 

Overview

I am a research clinician at International Diabetes Center (IDC). I work with patients participating in research studies related to type 1 and type 2 diabetes and new diabetes technology. For more information about the many studies offered through IDC, please call 952-993-3500. Being involved in diabetes research can help individuals better manage their diabetes or may help the next generation of people with diabetes. As Executive Director of the IDC, I also participate in training professionals in the US and internationally and publishing diabetes educational materials for patients and professionals. Translating new research findings into improvements in diabetes care is my major professional focus. We are finding that the best approach to improve care is by working as a team and to focus on the needs of each patient. My outreach diabetes clinic in Willmar Minnesota keeps me in clinical practice. My two granddaughters keep me active, amazed and inspired.

Dr. Bergenstal is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Type 2 Diabetes (T2D), Low Blood Sugar, Type 1 Diabetes (T1D), and Maturity Onset Diabetes of the Young.

Dr. Bergenstal is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine-Endocrin,Diabetes&Metabolism. He is actively involved in clinical research, co-authoring 289 peer reviewed articles and participating in 7 clinical trials.

Residency

University of Chicago Medical Center

Specialties

Endocrinology

Licenses

Internal Medicine in MN

Board Certifications

American Board Of Internal Medicine
American Board Of Internal Medicine-Endocrin,Diabetes&Metabolism

Fellowships

University of Chicago - 1982

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
View 5 Less Insurance Carriers -

Locations

Park Nicollet Specialty Center St. Louis Park 3800 Building
3800 Park, Nicollet, MN 55416

Additional Areas of Focus

Dr. Bergenstal has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Hypoparathyroidism
Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study
Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study
Enrollment Status: Completed
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drugs: Glimepiride, Sitagliptin, Liraglutide, Insulin (glargine)
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 3
Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects Utilizing Lyumjev® Insulin Lispro-aabc
Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects Utilizing Lyumjev® Insulin Lispro-aabc
Enrollment Status: Completed
Publish Date: January 15, 2025
Intervention Type: Device
Study Phase: Not Applicable
An Exploratory Study Assessing Time in Target Glucose Range Using a New Titration Scheme of LY900014 and Insulin Degludec in Patients With Type 1 Diabetes
An Exploratory Study Assessing Time in Target Glucose Range Using a New Titration Scheme of LY900014 and Insulin Degludec in Patients With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: June 03, 2022
Intervention Type: Drug
Study Drugs: LY900014, Insulin Degludec
Study Phase: Phase 2
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: January 19, 2022
Intervention Type: Drug
Study Phase: Phase 3
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Enrollment Status: Completed
Publish Date: March 05, 2019
Intervention Type: Device
Study Phase: Not Applicable
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Enrollment Status: Completed
Publish Date: March 13, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 6 Less Clinical Trials

289 Total Publications

Percent Time Below Range Is Strongly Associated with Clinically Important Level 2 Hypoglycemia Events in Individuals with Type 1 Diabetes.
Percent Time Below Range Is Strongly Associated with Clinically Important Level 2 Hypoglycemia Events in Individuals with Type 1 Diabetes.
Journal: Diabetes technology & therapeutics
Published: June 23, 2026
Similar Doctors
Expertise in
4
conditions
Expertise in
4
conditions
Referral required

M Health Fairview Endocrinology Clinic Minneapolis

909 Fulton Street Southeast, Floor 3, 
Minneapolis, MN 
 (6.1 miles away)
612-625-8690
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elizabeth Seaquist is an Endocrinologist practicing medicine in Minneapolis, Minnesota. She has been practicing medicine for over 44 years. Dr. Seaquist is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Low Blood Sugar, Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and Maturity Onset Diabetes of the Young. Dr. Seaquist is board certified in Internal Medicine: American Board Of Internal Medicine, 1985. Dr. Seaquist is currently accepting new patients.

Expertise in
15
conditions
Dr. Ann Kearns
Endocrinology
Expertise in
15
conditions
Dr. Ann Kearns
Endocrinology
Referral required

Hennepin Healthcare

701 Park Ave, 
Minneapolis, MN 
 (4.9 miles away)
612-873-7717
Languages Spoken:
English
See accepted insurances

Ann Kearns is an Endocrinologist practicing medicine in Minneapolis, Minnesota. Dr. Kearns is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Osteoporosis, Postmenopausal Osteoporosis, Hyperparathyroidism, Parathyroidectomy, and Hormone Replacement Therapy (HRT).

Expertise in
30
conditions
Dr. Takako Araki
Endocrinology
Expertise in
30
conditions
Dr. Takako Araki
Endocrinology
Referral required

M Health Fairview Endocrinology Clinic Minneapolis

909 Fulton Street Southeast, Floor 3, 
Minneapolis, MN 
 (6.1 miles away)
612-625-8690
Languages Spoken:
English, Japanese
See accepted insurances
Accepting New Patients
Offers Telehealth

Takako Araki is an Endocrinologist practicing medicine in Minneapolis, Minnesota. Dr. Araki is highly rated in 30 conditions, according to our data. Her clinical expertise encompasses Pituitary Tumor, Cushing's disease, Nelson Syndrome, Hypothalamic Tumor, and Deep Brain Stimulation. Dr. Araki is currently accepting new patients.

Frequently Asked Questions about Dr. Richard M. Bergenstal

How do I make an appointment with Dr. Richard M. Bergenstal?

You can book an appointment with Dr. Richard M. Bergenstal by calling their office at 952-993-1000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Richard M. Bergenstal a top-rated expert for Type 2 Diabetes (T2D)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Richard M. Bergenstal is classified as an Elite expert for Type 2 Diabetes (T2D), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Richard M. Bergenstal specialize in?

While Dr. Richard M. Bergenstal is a Endocrinology, they have specific expertise in Type 2 Diabetes (T2D), Low Blood Sugar, and Type 1 Diabetes (T1D). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Endocrinology.

Does Dr. Richard M. Bergenstal participate in research or clinical trials?

Yes. Dr. Richard M. Bergenstal has published 289 articles and abstracts on conditions like Type 2 Diabetes (T2D). You can view a list of Dr. Richard M. Bergenstal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Richard M. Bergenstal accept my insurance?

Dr. Richard M. Bergenstal accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 952-993-1000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bergenstal's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile